Aclaris Therapeutics (ACRS) Accounts Payables (2014 - 2026)

Aclaris Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 131.84% year-over-year to $14.7 million in Q1 2026; TTM through Mar 2026 was $14.7 million, a 131.84% increase from a year earlier, with the FY2025 full-year figure at $13.2 million, up 180.55% from the prior year.
• Accounts Payables grew to $14.7 million in Q1 2026 per ACRS's latest filing, from $13.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.7 million in Q1 2026 and bottomed at $4.7 million in Q4 2024.
• The 5-year median for Accounts Payables is $8.8 million (2025), against an average of $9.0 million.
• Across the five-year window, Accounts Payables plunged 47.17% in 2024 and jumped 180.55% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $10.4 million in 2022, then declined by 14.23% to $8.9 million in 2023, then sank by 47.17% to $4.7 million in 2024, then soared by 180.55% to $13.2 million in 2025, then grew by 11.95% to $14.7 million in 2026.
• Per Business Quant, the three latest ACRS Accounts Payables figures stand at $14.7 million (Q1 2026), $13.2 million (Q4 2025), and $9.2 million (Q3 2025).